This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Doisneau-Sixou, S. F. Articles by Favre, G. Search for Related Content PubMed PubMed Citation Articles by Doisneau-Sixou, S. F. Articles by Favre, G. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Hazardous Substances DB (L)-METHIONINE ESTRADIOL

Contrasting Effects of Prenyltransferase Inhibitors on Estrogen-Dependent Cell Cycle Progression and Estrogen Receptor-Mediated Transcriptional Activity in MCF-7 Cells

Département "Innovation Thérapeutique et Oncologie Moléculaire" (S.F.D.-S., P.C., S.C., M.P., J.-C.F., G.F.), Centre de Physiopathologie de Toulouse Purpan, Institut National de la Santé et de la Recherche Médicale U563, and Institut Claudius Regaud, 31052 Toulouse cedex, France; Cancer Research Program (S.F.D.-S., J.S.C., R.L.S.), Garvan Institute of Medical Research, St. Vincent’s Hospital, Darlinghurst, Sydney, New South Wales 2010, Australia; Department of Chemistry (A.D.H.), Yale University, New Haven, Connecticut 06511; Drug Discovery Program (S.M.S.), H. Lee Moffitt Cancer Center and Research Institute and Department of Biochemistry and Molecular Biology, University of South Florida, Tampa, Florida 33612; and Institut National de la Santé et de la Recherche Médicale 439 (P.B.), Pathologie Moléculaire des Récepteurs Nucléaires, 34090 Montpellier, France

Address all correspondence and requests for reprints to: Robert L. Sutherland, Garvan Institute of Medical Research, 384 Victoria Street, Darlinghurst, Sydney, New South Wales 2010, Australia. E-mail: r.sutherland{at}garvan.org.au.

Activation of estrogen receptors (ERs) by estrogens triggers both ER nuclear transcriptional activity and Src/Ras/Erks pathway-dependent mitogenic activity. The present study implicates prenylated proteins in both estrogenic actions. The farnesyltransferase and geranylgeranyltransferase I inhibitors (FTI-277 and GGTI-298, respectively) antagonize estradiol-stimulated cell cycle progression, progesterone receptor, cyclin D1, and c-Myc expression. In contrast, the inhibitors markedly stimulate transcription from two genes containing estrogen response elements, both in the absence and presence of estradiol. The pure antiestrogen ICI 182,780 inhibits by more than 85% these effects on transcription. We demonstrate that both FTI-277 and GGTI-298 increase the association of steroid receptor coactivator-1 with ER and FTI-277 decreases the association of ER with the histone deacetylase 1, a known transcriptional repressor. In addition, FTI-277 has no marked effect on the association of the two corepressors, nuclear receptor corepressor and silencing mediator of retinoid and thyroid receptor with ER, whereas GGTI-298, similar to tamoxifen, clearly increased these associations. Together, these results demonstrate that prenylated proteins play a role in estradiol stimulation of proliferation and progesterone receptor expression. However, they antagonize the ability of ER to stimulate estrogen response element-dependent transcriptional activity, acting presumably through coregulator complex formation.

This article has been cited by other articles:

				S. Das, M. Schapira, M. Tomic-Canic, R. Goyanka, T. Cardozo, and H. H. Samuels Farnesyl Pyrophosphate Is a Novel Transcriptional Activator for a Subset of Nuclear Hormone Receptors Mol. Endocrinol., November 1, 2007; 21(11): 2672 - 2686. [Abstract] [Full Text] [PDF]

				L.-A. Martin, J. E. Head, S. Pancholi, J. Salter, E. Quinn, S. Detre, S. Kaye, A. Howes, M. Dowsett, and S. R.D. Johnston The farnesyltransferase inhibitor R115777 (tipifarnib) in combination with tamoxifen acts synergistically to inhibit MCF-7 breast cancer cell proliferation and cell cycle progression in vitro and in vivo Mol. Cancer Ther., September 1, 2007; 6(9): 2458 - 2467. [Abstract] [Full Text] [PDF]

				P. de Medina, N. Boubekeur, P. Balaguer, G. Favre, S. Silvente-Poirot, and M. Poirot The Prototypical Inhibitor of Cholesterol Esterification, Sah 58-035 [3-[Decyldimethylsilyl]-N-[2-(4-methylphenyl)-1-phenylethyl]propanamide], Is an Agonist of Estrogen Receptors J. Pharmacol. Exp. Ther., October 1, 2006; 319(1): 139 - 149. [Abstract] [Full Text] [PDF]

				J. Igarashi-Migitaka, A. Takeshita, N. Koibuchi, S. Yamada, R. Ohtani-Kaneko, and K. Hirata Differential expression of p160 steroid receptor coactivators in the rat testis and epididymis Eur. J. Endocrinol., October 1, 2005; 153(4): 595 - 604. [Abstract] [Full Text] [PDF]

				O. Boijoux, C. Boutonnet, C. Giamarchi, G. Favre, S. Vagner, and J. C. Faye Chemical-Based Translational Induction of Luciferase Expression: An Efficient Tool for in Vivo Screening of Protein Farnesylation Inhibitors Mol. Pharmacol., June 1, 2005; 67(6): 1829 - 1833. [Abstract] [Full Text] [PDF]